BSA-LDHs-cGAMP In Situ Sensitization of Osteosarcoma: Enhancing Antitumor Efficacy with CD40 Agonist Antibodies
ACS Biomaterials Science & Engineering · 11.08.2025 · 11 (8) · 4931-4940
DOI: 10.1021/acsbiomaterials.5c00333 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Biomaterials Science & Engineering, online erschienen am 14.07.2025. Verfasst von Feng Yan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedics, The People's Hospital of Suzhou New District, Suzhou 215000, China. Hauptthemen laut MEDLINE: Osteosarcoma, Serum Albumin, Bovine, CD40 Antigens, Bone Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Postdoctoral Scientific Research Development Fund of Heilongjiang Province, Natural Science Foundation of Heilongjiang Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
Osteosarcoma is a malignant bone tumor that is extremely aggressive and presents several therapeutic problems. Although CD40 agonist antibodies (αCD40) have demonstrated potential in improving T cell priming and reprogramming tumor-associated macrophages, osteosarcoma's poor immunogenicity leads to "cold" tumors that are challenging to cure. When it comes to triggering immunological responses, the STING pathway is essential. To further improve this impact, cGAMP was stabilized and delivered using layered double hydroxide (LDH) nanoparticles cross-linked with bovine serum albumin (BSA). BSA-LDHs-cGAMP improved the infiltration of CD40+ macrophages and DC cells, which, in turn, improved the therapeutic impact of αCD40 immunotherapy. These results offer a promising in situ cancer treatment and show the possibility of αCD40 boosters in bone tumor therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Orthopedics, The People's Hospital of Suzhou New District, Suzhou 215000, China.
- Department of Nuclear Medicine, The First Affiliated Hospital of Ningbo University, Ningbo 315100, China.
- Department of Orthopedics, The Second Affiliated Hospital of Harbin Medical University, Harbin 150080, China.
- Jiangsu International Travel Healthcare Center, Suzhou Branch, Suzhou 215000, China.
- Department of Respiratory and Critical Care Medicine, Center for Oncology Medicine, The Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zheji…
- Zhejiang Key Laboratory of Precision Diagnosis and Treatment for Lung Cancer, Yiwu 322000, China.
ORCID-Profile: Weiyu Chen, Chao Li
Förderung
- Postdoctoral Scientific Research Development Fund of Heilongjiang Province
- Natural Science Foundation of Heilongjiang Province
- National Natural Science Foundation of China
- Jinhua Science and Technology Bureau
- Ningbo Yongjiang Talent Programme
- Ningbo Major Research and Development Plan Project
- Huadong Medicine Joint Funds of the Zhejiang Provincial Natural Science Foundation of China
- Suzhou Gusu Health Talents Program
Zitieren
APA
Yan, F., Jing, C., Duan, S., Xia, Y., Xiao, R., Shao, S., Xiao, Z., Chen, W., & Li, C. (2025). BSA-LDHs-cGAMP In Situ Sensitization of Osteosarcoma: Enhancing Antitumor Efficacy with CD40 Agonist Antibodies. ACS Biomaterials Science & Engineering, 11(8), 4931-4940. https://doi.org/10.1021/acsbiomaterials.5c00333
Vancouver
Yan F, Jing C, Duan S, Xia Y, Xiao R, Shao S, et al. BSA-LDHs-cGAMP In Situ Sensitization of Osteosarcoma: Enhancing Antitumor Efficacy with CD40 Agonist Antibodies. ACS Biomaterials Science & Engineering. 2025;11(8):4931-4940. doi:10.1021/acsbiomaterials.5c00333
BibTeX
@article{Yan2025,
author = {Yan, Feng and Jing, Chengwei and Duan, Shao and Xia, Yifei and Xiao, Runzhu and Shao, Shuaiming and Xiao, Zunyu and Chen, Weiyu and Li, Chao},
title = {BSA-LDHs-cGAMP In Situ Sensitization of Osteosarcoma: Enhancing Antitumor Efficacy with CD40 Agonist Antibodies},
journal = {ACS Biomaterials Science & Engineering},
year = {2025},
volume = {11},
number = {8},
pages = {4931--4940},
doi = {10.1021/acsbiomaterials.5c00333}
}
EUVIMED